Shopping Cart
- Remove All
- Your shopping cart is currently empty
ABX-IL8 is a humanized antibody targeting IL-8, which interferes with the tubular formation of human umbilical vein endothelial cells, inhibiting angiogenesis, tumor growth, and metastasis in human melanoma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $183 | In Stock | |
5 mg | $448 | In Stock | |
10 mg | $715 | In Stock | |
25 mg | $1,080 | In Stock | |
50 mg | $1,460 | In Stock |
Description | ABX-IL8 is a humanized antibody targeting IL-8, which interferes with the tubular formation of human umbilical vein endothelial cells, inhibiting angiogenesis, tumor growth, and metastasis in human melanoma. |
In vitro | ABX-IL8 (100 μg/ml) did not affect the proliferation of A375SM and TXM-13 melanoma cells, but down-regulated the activity of MMP-2 metalloproteinase, which inhibited the invasion of human melanoma cells. ABX-IL8 (100 μg/ml) directly interferes with tubule formation of human umbilical vein endothelial cells. [1] ABX-IL8 blocking IL-8 significantly inhibited the expression, activity, and transcription of MMP-2 and MMP-9, resulting in reduced invasion through remodeling the basement membrane in vitro. [2] |
In vivo | In nude mice treated with ABX-IL8 (1 mg/3 times weekly, intrabitoneal injection for 3 weeks) subcutaneously injected with A375SM and TXM-13, results showed that tumor growth of both types of melanoma was significantly inhibited in ABX-IL8-treated mice. [1] |
Alias | Anti-IL-8 antibody, ABXIL8 |
Molecular Weight | 145.5 kDa |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.